grey market retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and Drug Retatrutide and the Grey Market:

2020 doi: 10.1210/clinem/dgz175

In a study involving healthy non-diabetic subjects, daily intake of a Lactobacillus reuteri SD5865 strain for 8 weeks resulted in an increase of GLP-1 secretion in the intestines, which was accompanied by elevated plasma insulin and C-peptide levels [109]

You can read the full article Weight Loss and Hypertension in Obese Subjects PMC (nih.gov)

Wilding JPH et al

The secondary patents that extend effective market exclusivity are concentrated in two developmental windows: the formulation and manufacturing process work done during Phase I, and the indication and dosing discoveries that emerge from Phase II and III